Nitroglycerin is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. It is available as sublingual tablets, transdermal patches and ointment for intravenous use. MedsAcross supplies Nitroglycerin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Nitroglycerin Lingual Spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin Lingual Spray is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
Source: US FDA prescribing information
Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This eventually leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in vasodilatation.
Source: US FDA prescribing information
At the onset of an attack, administer onto or under the tongue. Repeat every 5 minutes as needed. Do up to three metered sprays within a 15-minute period. If chest pain persists, advise prompt medical attention. May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.
Source: US FDA prescribing information
Use of phosphodiesterase type 5 (PDE-5) Inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Severe anemia. Increased intracranial pressure. Hypersensitivity to Nitroglycerin Lingual Spray or to other nitrates or nitrites or any excipient.
Source: US FDA prescribing information
Tolerance: Excessive use may lead to tolerance. Hypotension: Severe hypotension may occur. Tolerance Excessive use may lead to the development of tolerance. Only the smallest number of doses required for effective relief of the acute angina attack should be used. 5. 2 Hypotension Severe hypotension, particularly with upright posture, may occur even with small doses of nitroglycerin particularly in patients with constrictive pericarditis, aortic or mitral stenosis, patients who may be volume-depleted, or are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. Symptoms of severe hypotension (nausea, vomiting, weakness, pallor, perspiration and collapse/syncope) may occur even with therapeutic doses.
Source: US FDA prescribing information
Most common adverse reactions occurring at a frequency greater than 2 % are headache, dizzinesss and paresthesia.
Source: US FDA prescribing information
Antihypertensives: Possible additive hypotensive effects. Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use 7. 1 P DE -5- I nhibitors and sGC- S timulators Nitroglycerin Lingual Spray is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. Nitroglycerin Lingual Spray is contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators. Concomitant use can cause hypotension. The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended.
Source: US FDA prescribing information
Store at 20°C – 25°C (68°F – 77°F), excursions permitted to 15°C – 30°C (59°F – 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
33 presentations of Nitroglycerin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nitroglycerin 0.4 mg sublingual tabletSublingualGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.3 mg sublingual tabletSublingualGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.6 mg sublingual tabletSublingualGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.4% ointmentRectalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 400 mcg oral sprayOralGeneric name | — | US FDA | Available on request |
| Nitrostat 0.4 mg sublingual tabletSublingual | Viatris Specialty | US FDA | Available on request |
| Nitroglycerin 50 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Nitroglycerin 2% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Nitro-bid 2% ointmentTopical | Savage Laboratories | US FDA | Available on request |
| Nitroglycerin 25 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Nitroglycerin 50 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| nitroglycerin lingual 400 mcg oral sprayOral | Padagis Israel Pharmaceuticals | US FDA | Available on request |
| Nitrolingual 400 mcg oral sprayOral | Independence Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 120 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 160 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 20 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 40 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 60 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitro-dur 80 mg transdermal patchTransdermal | Ingenus Pharmaceuticals | US FDA | Available on request |
| Nitroglycerin 0.1 mg/hour transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.2 mg/hour transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.4 mg/hour transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 0.6 mg/hour transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 100 mg/20 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Nitroglycerin 100 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Nitroglycerin 120 mg transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 20 mg transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 40 mg transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin 80 mg transdermal patchTransdermalGeneric name | — | US FDA | Available on request |
| Nitroglycerin Lingual 400 mcg oral sprayOral | Allegis Pharmaceuticals | US FDA | Available on request |
| Nitrostat 0.3 mg sublingual tabletSublingual | Viatris Specialty | US FDA | Available on request |
| Nitrostat 0.6 mg sublingual tabletSublingual | Viatris Specialty | US FDA | Available on request |
| Rectiv 0.4% ointmentRectal | Allergan | US FDA | Available on request |
6 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 September 1981 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Nitroglycerin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 33 presentations of Nitroglycerin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 7 brand names for Nitroglycerin, including Nitro-bid, Nitro-dur, nitroglycerin lingual, Nitroglycerin Lingual, Nitrolingual, Nitrostat, Rectiv.
Yes. The US FDA first approved Nitroglycerin on 30 September 1981, according to Drugs@FDA.
No listed presentation of Nitroglycerin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Nitroglycerin is classified under ATC code C01DA02 (Nitroglycerin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.